Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Autoimmune Disorders01:29

Autoimmune Disorders

Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune system...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Residual inflammation in the cerebrospinal fluid after short- and long-term natalizumab treatment in relapsing-remitting multiple sclerosis.

Frontiers in immunology·2026
Same author

Cognitively stimulating activities in multiple sclerosis: Results of a randomized controlled trial.

Multiple sclerosis and related disorders·2026
Same author

Delayed transcallosal conduction to the lesioned sensorimotor cortex in multiple Sclerosis: A combined TMS 7 T-MRI study.

NeuroImage. Clinical·2026
Same author

Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort study.

Journal of neurology, neurosurgery, and psychiatry·2026
Same author

Cerebrospinal Fluid sCD27 as a Biomarker of Neuroinflammatory Disease: A Systematic Review and Meta-Analysis.

Journal of neurochemistry·2026
Same author

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials.

Diabetes, obesity & metabolism·2026

Related Experiment Video

Updated: Jun 5, 2026

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis
05:55

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis

Published on: December 1, 2023

Interferon-beta increases systemic BAFF levels in multiple sclerosis without increasing autoantibody production.

Chris J Hedegaard1, Finn Sellebjerg, Martin Krakauer

  • 1Institute for Inflammation Research, Department of Rheumatology, Copenhagen University Hospital, Rigshospitalet, Denmark.

Multiple Sclerosis (Houndmills, Basingstoke, England)
|December 24, 2010
PubMed
Summary

B-cell activating factor (BAFF) levels correlate with disability in multiple sclerosis (MS) patients. Interferon-beta (IFN-beta) therapy increases BAFF but decreases anti-myelin basic protein (MBP) autoantibodies in MS.

More Related Videos

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

Related Experiment Videos

Last Updated: Jun 5, 2026

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis
05:55

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis

Published on: December 1, 2023

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

Area of Science:

  • Neuroimmunology
  • Autoimmunity
  • Biomarkers in Multiple Sclerosis

Background:

  • Interferon-beta (IFN-beta) treatment for multiple sclerosis (MS) elevates B-cell activating factor (BAFF) expression.
  • This raises concerns about potential activation of autoimmune B cells and increased autoantibody production in MS patients.

Purpose of the Study:

  • To determine if BAFF levels correlate with disease severity or activity in untreated MS patients.
  • To evaluate the impact of IFN-beta therapy on circulating BAFF and anti-myelin basic protein (MBP) autoantibody levels.

Main Methods:

  • Longitudinal study of 23 relapsing-remitting MS patients initiating IFN-beta therapy.
  • Measurement of BAFF, IgM, and IgG anti-MBP autoantibodies at baseline and follow-up points (up to 26 months).
  • Correlation analysis with Expanded Disability Status Scale (EDSS) and MS Severity Score (MSSS).

Main Results:

  • Baseline BAFF levels positively correlated with EDSS and MSSS in untreated MS patients.
  • IFN-beta therapy led to a sustained increase in plasma BAFF levels at 3 and 6 months.
  • A significant decrease in both IgM and IgG anti-MBP autoantibodies was observed after 6 months of IFN-beta therapy.

Conclusions:

  • Elevated BAFF levels before treatment are associated with higher disability scores in MS, indicating a potential negative prognostic marker.
  • IFN-beta therapy increases BAFF levels but does not lead to a rise in anti-MBP autoantibodies, suggesting a complex immunomodulatory effect.